Changes in the Myocardial Interstitium and Contribution to the Progression of Heart Failure

Heart Failure Clinics

Volumn 8, Issue 1, 2012, Pages 7-20

  Eckhouse, Shaina R ^a   Spinale, Francis G ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Dilated cardiomyopathy; Extracellular matrix; Heart failure; Interstitium; Myocardial infarction; Pressure overload hypertrophy

Indexed keywords

FIBRILLAR COLLAGEN; FIBRONECTIN; GALECTIN 3; GELATINASE A; GELATINASE B; INTEGRIN; INTERSTITIAL COLLAGENASE; LAMININ; MATRIX METALLOPROTEINASE 14; NEUTROPHIL COLLAGENASE; OSTEONECTIN; STROMELYSIN; THROMBOSPONDIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TRANSFORMING GROWTH FACTOR;

AORTA STENOSIS; CONGESTIVE CARDIOMYOPATHY; DISEASE COURSE; EXTRACELLULAR MATRIX; GENE DELETION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART TRANSPLANTATION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HUMAN; HYPERTENSION; INTERSTITIUM; INTRACELLULAR SIGNALING; ISCHEMIC HEART DISEASE; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; REVIEW;

ANIMALS; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; HEART FAILURE; HUMANS; MYOCARDIUM; VENTRICULAR REMODELING;

EID: 82955246213     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2011.08.012     Document Type: Review

References (109)

1. Brower G.L., Gardner J.D., Forman M.F., et al. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg 2006, 30(4):604-610.
2. Bowers S.L., Banerjee I., Baudino T.A. The extracellular matrix: at the center of it all. J Mol Cell Cardiol 2010, 48(3):474-482.
3. Baumgarten G., Knuefermann P., Kalra D., et al. Load-dependent and -independent regulation of proinflammatory cytokine and cytokine receptor gene expression in the adult mammalian heart. Circulation 2002, 105(18):2192-2197.
4. Booz G.W., Baker K.M. Molecular signalling mechanisms controlling growth and function of cardiac fibroblasts. Cardiovasc Res 1995, 30(4):537-543.
5. Briest W., Homagk L., Rassler B., et al. Norepinephrine-induced changes in cardiac transforming growth factor-beta isoform expression pattern of female and male rats. Hypertension 2004, 44(4):410-418.
6. Chen K., Mehta J.L., Li D., et al. Transforming growth factor beta receptor endoglin is expressed in cardiac fibroblasts and modulates profibrogenic actions of angiotensin II. Circ Res 2004, 95(12):1167-1173.
7. Dell'Italia L.J., Meng Q.C., Balcells E., et al. Compartmentalization of angiotensin II generation in the dog heart. Evidence for independent mechanisms in intravascular and interstitial spaces. J Clin Invest 1997, 100(2):253-258.
8. Diwan A., Dibbs Z., Nemoto S., et al. Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation 2004, 109(2):262-268.
9. Ergul A., Walker C.A., Goldberg A., et al. ET-1 in the myocardial interstitium: relation to myocyte ECE activity and expression. Am J Physiol Heart Circ Physiol 2000, 278(6):H2050-H2056.
10. Filion R.J., Popel A.S. Intracoronary administration of FGF-2: a computational model of myocardial deposition and retention. Am J Physiol Heart Circ Physiol 2005, 288(1):H263-H279.
11. Frangogiannis N.G., Ren G., Dewald O., et al. Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation 2005, 111(22):2935-2942.
12. Fuchs S., Skwara A., Bloch M., et al. Differential induction and regulation of matrix metalloproteinases in osteoarthritic tissue and fluid synovial fibroblasts. Osteoarthr Cartil 2004, 12(5):409-418.
13. Multani M.M., Ikonomidis J.S., Kim P.Y., et al. Dynamic and differential changes in myocardial and plasma endothelin in patients undergoing cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005, 129(3):584-590.
14. Rodriguez-Vita J., Ruiz-Ortega M., Ruperez M., et al. Endothelin-1, via ETA receptor and independently of transforming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells. Circ Res 2005, 97(2):125-134.
15. Romero J.R., Rivera A., Lanca V., et al. Na+/Ca2+ exchanger activity modulates connective tissue growth factor mRNA expression in transforming growth factor beta1- and Des-Arg10-kallidin-stimulated myofibroblasts. J Biol Chem 2005, 280(15):14378-14384.
16. Wei C.C., Meng Q.C., Palmer R., et al. Evidence for angiotensin-converting enzyme- and chymase-mediated angiotensin II formation in the interstitial fluid space of the dog heart in vivo. Circulation 1999, 99(19):2583-2589.
17. Gunja-Smith Z., Morales A.R., Romanelli R., et al. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. Am J Pathol 1996, 148(5):1639-1648.
18. Burlew B.S., Weber K.T. Connective tissue and the heart. Functional significance and regulatory mechanisms. Cardiol Clin 2000, 18(3):435-442.
19. Cleutjens J.P., Verluyten M.J., Smiths J.F., et al. Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol 1995, 147(2):325-338.
20. Keller R.S., Shai S.Y., Babbitt C.J., et al. Disruption of integrin function in the murine myocardium leads to perinatal lethality, fibrosis, and abnormal cardiac performance. Am J Pathol 2001, 158(3):1079-1090.
21. Hornberger L.K., Singhroy S., Cavalle-Garrido T., et al. Synthesis of extracellular matrix and adhesion through beta(1) integrins are critical for fetal ventricular myocyte proliferation. Circ Res 2000, 87(6):508-515.
22. Spinale F.G., Tomita M., Zellner J.L., et al. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol 1991, 261(2 Pt 2):H308-H318.
23. Stroud J.D., Baicu C.F., Barnes M.A., et al. Viscoelastic properties of pressure overload hypertrophied myocardium: effect of serine protease treatment. Am J Physiol Heart Circ Physiol 2002, 282(6):H2324-H2335.
24. Baicu C.F., Stroud J.D., Livesay V.A., et al. Changes in extracellular collagen matrix alter myocardial systolic performance. Am J Physiol Heart Circ Physiol 2003, 284(1):H122-H132.
25. Ross R.S., Borg T.K. Integrins and the myocardium. Circ Res 2001, 88(11):1112-1119.
26. Nimni M.E. Fibrillar collagens: their biosynthesis, molecular structure, and mode of assembly. Extracellular matrix 1993, 121-148. Marcel Dekker, Inc, New York. M.A. Zern, L.M. Reid (Eds.).
27. Borg T.K., Klevay L.M., Gay R.E., et al. Alteration of the connective tissue network of striated muscle in copper deficient rats. J Mol Cell Cardiol 1985, 17(12):1173-1183.
28. Fomovsky G.M., Thomopoulos S., Holmes J.W. Contribution of extracellular matrix to the mechanical properties of the heart. J Mol Cell Cardiol 2010, 48(3):490-496.
29. Kato S., Spinale F.G., Tanaka R., et al. Inhibition of collagen cross-linking: effects on fibrillar collagen and ventricular diastolic function. Am J Physiol 1995, 269(3 Pt 2):H863-H868.
30. Asif M., Egan J., Vasan S., et al. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci U S A 2000, 97(6):2809-2813.
31. Levene C.I. Diseases of the collagen molecule. J Clin Pathol Suppl (R Coll Pathol) 1978, 12:82-94.
32. Kunicki T.J. The role of platelet collagen receptor (glycoprotein Ia/IIa; integrin alpha2 beta1) polymorphisms in thrombotic disease. Curr Opin Hematol 2001, 8(5):277-285.
33. Kuettner K.E., Kimura J.H. Proteoglycans: an overview. J Cell Biochem 1985, 27(4):327-336.
34. Sivasubramanian N., Coker M.L., Kurrelmeyer K.M., et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2001, 104(7):826-831.
35. Bradham W.S., Bozkurt B., Gunasinghe H., et al. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res 2002, 53(4):822-830.
36. Fowlkes J.L., Winkler M.K. Exploring the interface between metallo-proteinase activity and growth factor and cytokine bioavailability. Cytokine Growth Factor Rev 2002, 13(3):277-287.
37. Ogawa E., Saito Y., Harada M., et al. Outside-in signalling of fibronectin stimulates cardiomyocyte hypertrophy in cultured neonatal rat ventricular myocytes. J Mol Cell Cardiol 2000, 32(5):765-776.
38. Bradshaw A.D., Sage E.H. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 2001, 107(9):1049-1054.
39. McCurdy S., Baicu C.F., Heymans S., et al. Cardiac extracellular matrix remodeling: fibrillar collagens and Secreted Protein Acidic and Rich in Cysteine (SPARC). J Mol Cell Cardiol 2010, 48(3):544-549.
40. Schellings M.W., Vanhoutte D., Swinnen M., et al. Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J Exp Med 2009, 206(1):113-123.
41. Bradshaw A.D., Baicu C.F., Rentz T.J., et al. Pressure overload-induced alterations in fibrillar collagen content and myocardial diastolic function: role of secreted protein acidic and rich in cysteine (SPARC) in post-synthetic procollagen processing. Circulation 2009, 119(2):269-280.
42. Bornstein P. Thrombospondins as matricellular modulators of cell function. J Clin Invest 2001, 107(8):929-934.
43. Schroen B., Heymans S., Sharma U., et al. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res 2004, 95(5):515-522.
44. Schellings M.W., Pinto Y.M., Heymans S. Matricellular proteins in the heart: possible role during stress and remodeling. Cardiovasc Res 2004, 64(1):24-31.
45. Murphy-Ullrich J.E., Gurusiddappa S., Frazier W.A., et al. Heparin-binding peptides from thrombospondins 1 and 2 contain focal adhesion-labilizing activity. J Biol Chem 1993, 268(35):26784-26789.
46. Spinale F.G. Cell-matrix signaling and thrombospondin: another link to myocardial matrix remodeling. Circ Res 2004, 95(5):446-448.
47. Swinnen M., Vanhoutte D., Van Almen G.C., et al. Absence of thrombospondin-2 causes age-related dilated cardiomyopathy. Circulation 2009, 120(16):1585-1597.
48. Shah R.V., Chen-Tournoux A.A., Picard M.H., et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010, 12(8):826-832.
49. Zile M.R., DeSantis S.M., Baicu C.F., et al. Plasma galectin-3 levels and relation to left ventricular function and the determinants of matrix composition in hypertensive heart disease. Circulation 2010, 122(Suppl 21):A12433.
50. Border W.A., Noble N.A. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994, 331(19):1286-1292.
51. Leask A. TGFbeta, cardiac fibroblasts, and the fibrotic response. Cardiovasc Res 2007, 74(2):207-212.
52. Lijnen P.J., Petrov V.V., Fagard R.H. Induction of cardiac fibrosis by transforming growth factor-beta(1). Mol Genet Metab 2000, 71(1-2):418-435.
53. Hausenloy D.J., Yellon D.M. Cardioprotective growth factors. Cardiovasc Res 2009, 83(2):179-194.
54. Seeland U., Haeuseler C., Hinrichs R., et al. Myocardial fibrosis in transforming growth factor-beta(1) (TGF-beta(1)) transgenic mice is associated with inhibition of interstitial collagenase. Eur J Clin Invest 2002, 32(5):295-303.
55. Frantz S., Hu K., Adamek A., et al. Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol 2008, 103(5):485-492.
56. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007, 87(4):1285-1342.
57. Chapman R.E., Spinale F.G. Extracellular protease activation and unraveling of the myocardial interstitium: critical steps toward clinical applications. Am J Physiol Heart Circ Physiol 2004, 286(1):H1-H10.
58. Poole-Wilson P.A. Relation of pathophysiologic mechanisms to outcome in heart failure. J Am Coll Cardiol 1993, 22(4 Suppl A):22A-29A.
59. Douglas P.S., Morrow R., Ioli A., et al. Left ventricular shape, afterload and survival in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1989, 13(2):311-315.
60. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006, 69(3):562-573.
61. Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 2006, 11:1696-1701.
62. Hwang I.K., Park S.M., Kim S.Y., et al. A proteomic approach to identify substrates of matrix metalloproteinase-14 in human plasma. Biochim Biophys Acta 2004, 1702(1):79-87.
63. Thomas C.V., Coker M.L., Zellner J.L., et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998, 97(17):1708-1715.
64. Spinale F.G., Coker M.L., Heung L.J., et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 2000, 102(16):1944-1949.
65. Li Y.Y., Feldman A.M., Sun Y., et al. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998, 98(17):1728-1734.
66. Lovelock J.D., Baker A.H., Gao F., et al. Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2005, 288(2):H461-H468.
67. Guedez L., Stetler-Stevenson W.G., Wolff L., et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 1998, 102(11):2002-2010.
68. Fielitz J., Leuschner M., Zurbrugg H.R., et al. Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis. J Mol Med 2004, 82(12):809-820.
69. Polyakova V., Hein S., Kostin S., et al. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol 2004, 44(8):1609-1618.
70. Heymans S., Schroen B., Vermeersch P., et al. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 2005, 112(8):1136-1144.
71. Hess O.M., Ritter M., Schneider J., et al. Diastolic stiffness and myocardial structure in aortic valve disease before and after valve replacement. Circulation 1984, 69(5):855-865.
72. Monrad E.S., Hess O.M., Murakami T., et al. Time course of regression of left ventricular hypertrophy after aortic valve replacement. Circulation 1988, 77(6):1345-1355.
73. Villari B., Vassalli G., Monrad E.S., et al. Normalization of diastolic dysfunction in aortic stenosis late after valve replacement. Circulation 1995, 91(9):2353-2358.
74. Krayenbuehl H.P., Hess O.M., Monrad E.S., et al. Left ventricular myocardial structure in aortic valve disease before, intermediate, and late after aortic valve replacement. Circulation 1989, 79(4):744-755.
75. Villari B., Campbell S.E., Hess O.M., et al. Influence of collagen network on left ventricular systolic and diastolic function in aortic valve disease. J Am Coll Cardiol 1993, 22(5):1477-1484.
76. Zile M.R., Baicu C.F., Gaasch W.H. Diastolic heart failure-abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004, 350(19):1953-1959.
77. Villar A.V., Llano M., Cobo M., et al. Gender differences of echocardiographic and gene expression patterns in human pressure overload left ventricular hypertrophy. J Mol Cell Cardiol 2009, 46(4):526-535.
78. Lopez B., Gonzalez A., Querejeta R., et al. The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. J Hypertens 2005, 23(8):1445-1451.
79. Laviades C., Varo N., Fernandez J., et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998, 98(6):535-540.
80. Timms P.M., Wright A., Maxwell P., et al. Plasma tissue inhibitor of metalloproteinase-1 levels are elevated in essential hypertension and related to left ventricular hypertrophy. Am J Hypertens 2002, 15(3):269-272.
81. Tayebjee M.H., Nadar S.K., MacFadyen R.J., et al. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension Relationship to tissue Doppler indices of diastolic relaxation. Am J Hypertens 2004, 17(9):770-774.
82. Barton P.J., Birks E.J., Felkin L.E., et al. Increased expression of extracellular matrix regulators TIMP1 and MMP1 in deteriorating heart failure. J Heart Lung Transplant 2003, 22(7):738-744.
83. Herpel E., Singer S., Flechtenmacher C., et al. Extracellular matrix proteins and matrix metalloproteinases differ between various right and left ventricular sites in end-stage cardiomyopathies. Virchows Arch 2005, 446(4):369-378.
84. Klotz S., Foronjy R.F., Dickstein M.L., et al. Mechanical unloading during left ventricular assist device support increases left ventricular collagen cross-linking and myocardial stiffness. Circulation 2005, 112(3):364-374.
85. Li Y.Y., Feng Y., McTiernan C.F., et al. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 2001, 104(10):1147-1152.
86. Mukherjee R., Herron A.R., Lowry A.S., et al. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol 2006, 97(4):532-537.
87. Felkin L.E., Lara-Pezzi E., George R., et al. Expression of extracellular matrix genes during myocardial recovery from heart failure after left ventricular assist device support. J Heart Lung Transplant 2009, 28(2):117-122.
88. Batlle M., Perez-Villa F., Lazaro A., et al. Decreased expression of thrombospondin-1 in failing hearts may favor ventricular remodeling. Transplant Proc 2009, 41(6):2231-2233.
89. Bruggink A.H., van Oosterhout M.F., de Jonge N., et al. Reverse remodeling of the myocardial extracellular matrix after prolonged left ventricular assist device support follows a biphasic pattern. J Heart Lung Transplant 2006, 25(9):1091-1098.
90. Erlebacher J.A., Weiss J.L., Weisfeldt M.L., et al. Early dilation of the infarcted segment in acute transmural myocardial infarction: role of infarct expansion in acute left ventricular enlargement. J Am Coll Cardiol 1984, 4(2):201-208.
91. Pfeffer M.A., Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990, 81(4):1161-1172.
92. Sutton M.G., Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000, 101(25):2981-2988.
93. St John Sutton M., Pfeffer M.A., Plappert T., et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation 1994, 89(1):68-75.
94. Doughty R.N., Whalley G.A., Gamble G., et al. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997, 29(5):1060-1066.
95. Spinale F.G., Koval C.N., Deschamps A.M., et al. Dynamic changes in matrix metalloproteinase activity within the human myocardial interstitium during myocardial arrest and reperfusion. Circulation 2008, 118(Suppl 14):S16-S23.
96. Dinh W., Futh R., Scheffold T., et al. Increased serum levels of tissue inhibitor of metalloproteinase-1 in patients with acute myocardial infarction. Int Heart J 2009, 50(4):421-431.
97. McGavigan A.D., Maxwell P.R., Dunn F.G. Serological evidence of altered collagen homeostasis reflects early ventricular remodeling following acute myocardial infarction. Int J Cardiol 2006, 111(2):267-274.
98. Hlatky M.A., Ashley E., Quertermous T., et al. Matrix metalloproteinase circulating levels, genetic polymorphisms, and susceptibility to acute myocardial infarction among patients with coronary artery disease. Am Heart J 2007, 154(6):1043-1051.
99. Kai H., Ikeda H., Yasukawa H., et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998, 32(2):368-372.
100. Squire I.B., Evans J., Ng L.L., et al. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 2004, 10(4):328-333.
101. Wagner D.R., Delagardelle C., Ernens I., et al. Matrix metalloproteinase-9 is a marker of heart failure after acute myocardial infarction. J Card Fail 2006, 12(1):66-72.
102. van den Borne S.W., Cleutjens J.P., Hanemaaijer R., et al. Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction. Cardiovasc Pathol 2009, 18(1):37-43.
103. Ahmed S.H., Clark L.L., Pennington W.R., et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006, 113(17):2089-2096.
104. Kelly D., Cockerill G., Ng L.L., et al. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 2007, 28(6):711-718.
105. Webb C.S., Bonnema D.D., Ahmed S.H., et al. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation 2006, 114(10):1020-1027.
106. Zannad F., Alla F., Dousset B., et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 2000, 102(22):2700-2706.
107. Zile M.R., DeSantis S.M., Baicu C.F., et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail 2011, 4(3):246-256.
108. Sundstrom J., Evans J.C., Benjamin E.J., et al. Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study. Eur Heart J 2004, 25(17):1509-1516.
109. Iraqi W., Rossignol P., Angioi M., et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 2009, 119(18):2471-2479.